Elham Rismani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elham Rismani has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Massoud Vosough
Royan Institute for Stem Cell Biology and Technology, ACECR
9 shared publications Ladan Mafakher
Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 shared publications- Moustapha Hassan
Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
3 shared publications - Pedram Asadi Sarabi
Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
3 shared publications - Abbas Piryaei
Department of Biology and Anatomical Sciences, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran
2 shared publications - Abbasali Raz
Malaria and Vector Research Group, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by MDPI AG in Journal of Genome Biotechnology and Genetics
- Vol. 1 (3) , 19
Computational Design and Structure-Guided Optimization of Anti-Osteopontin Monoclonal Antibodies at the Intersection of Obesity, Type 2 Diabetes, and Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, and obesity and type 2 diabetes (T2D) are recognized metabolic risk factors for its development. In this study, disease-associated gene lists for T2D and obesity were integrated with differentially expressed genes from the Cancer Genome Atlas Liver Hepatocellular Carcinoma cohort (TCGA-LIHC). Analysis of 371 primary HCC and 50 solid-tissue normal samples identified 2123 differentially expressed genes, including 715 upregulated and 1408 downregulated genes. The intersection of the 715 upregulated genes with 2055 T2D-associated and 1944 obesity-associated protein-coding genes identified 29 common candidates. Functional annotation identified 14 extracellular-region genes, which were evaluated using protein–protein interaction analysis and ranked using the maximal clique centrality algorithm. SPP1, encoding Osteopontin (OPN), was the highest-ranked candidate. SPP1 expression distinguished HCC from non-tumor tissues with an area under the receiver operating characteristic curve of 0.714 (95% confidence interval: 0.666–0.760). High SPP1 expression was associated with poorer overall survival, and continuous log2-transformed SPP1 expression remained independently associated with survival after adjustment for age, sex, and pathological stage. OPN was subsequently subjected to structural modeling, molecular dynamics simulation, B-cell epitope prediction, and the structure-guided optimization of anti-OPN monoclonal antibodies. Molecular docking and binding affinity analyses revealed that optimized mAbs exhibited predicted Kd values corresponding to approximately 10- to 650-fold stronger binding affinity and increased predicted hydrogen bonding at the interface. These findings support SPP1 as a promising immunotherapeutic target in metabolically driven HCC, warranting further experimental validation.
- 6 October 2026
- Published by MDPI AG in Journal of Genome Biotechnology and Genetics
- Vol. 1 (3) , 19
Open AccessComputational Design and Structure-Guided Optimization of Anti-Osteopontin Monoclonal Antibodies at the Intersection of Obesity, Type 2 Diabetes, and Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, and obesity and type 2 diabetes (T2D) are recognized metabolic risk factors for its development. In this study, disease-associated gene lists for T2D and obesity were integrated with differentially expressed genes from the Cancer Genome Atlas Liver Hepatocellular Carcinoma cohort (TCGA-LIHC). Analysis of 371 primary HCC and 50 solid-tissue normal samples identified 2123 differentially expressed genes, including 715 upregulated and 1408 downregulated genes. The intersection of the 715 upregulated genes with 2055 T2D-associated and 1944 obesity-associated protein-coding genes identified 29 common candidates. Functional annotation identified 14 extracellular-region genes, which were evaluated using protein–protein interaction analysis and ranked using the maximal clique centrality algorithm. SPP1, encoding Osteopontin (OPN), was the highest-ranked candidate. SPP1 expression distinguished HCC from non-tumor tissues with an area under the receiver operating characteristic curve of 0.714 (95% confidence interval: 0.666–0.760). High SPP1 expression was associated with poorer overall survival, and continuous log2-transformed SPP1 expression remained independently associated with survival after adjustment for age, sex, and pathological stage. OPN was subsequently subjected to structural modeling, molecular dynamics simulation, B-cell epitope prediction, and the structure-guided optimization of anti-OPN monoclonal antibodies. Molecular docking and binding affinity analyses revealed that optimized mAbs exhibited predicted Kd values corresponding to approximately 10- to 650-fold stronger binding affinity and increased predicted hydrogen bonding at the interface. These findings support SPP1 as a promising immunotherapeutic target in metabolically driven HCC, warranting further experimental validation.
- 24 September 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (11) , 293
Natural killer cell-based therapy for hepatocellular carcinoma (HCC): A literature review
- 24 September 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (11) , 293
Natural killer cell-based therapy for hepatocellular carcinoma (HCC): A literature review
- Open Access
- 31 July 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (4)
3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening
Liver fibrosis is the common consequence of liver injury caused by a variety of chronic liver disorders. This condition leads to the development of more severe complications, particularly cirrhosis and hepatocellular carcinoma. Despite abundant studies, the fundamental cell and molecular mechanisms of liver fibrosis are still unknown. There are many key players involved in the initiation and progression of liver fibrosis. Thus, the specific type of underlying disease and the study's objectives should be considered while choosing suitable models for liver fibrosis. Numerous in vitro and in vivo models have been generated to investigate liver fibrosis and proposed for drug screening and toxicology; however, there are no ideal in vitro models for drug discovery yet. In this review, we introduced the available in vitro models and highlighted certain platforms such as organoids and liver‐on‐a‐chip for investigating liver fibrosis. Furthermore, we discussed the current challenges and potential application of each model.
- 31 July 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (4)
Open Access3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening
Liver fibrosis is the common consequence of liver injury caused by a variety of chronic liver disorders. This condition leads to the development of more severe complications, particularly cirrhosis and hepatocellular carcinoma. Despite abundant studies, the fundamental cell and molecular mechanisms of liver fibrosis are still unknown. There are many key players involved in the initiation and progression of liver fibrosis. Thus, the specific type of underlying disease and the study's objectives should be considered while choosing suitable models for liver fibrosis. Numerous in vitro and in vivo models have been generated to investigate liver fibrosis and proposed for drug screening and toxicology; however, there are no ideal in vitro models for drug discovery yet. In this review, we introduced the available in vitro models and highlighted certain platforms such as organoids and liver‐on‐a‐chip for investigating liver fibrosis. Furthermore, we discussed the current challenges and potential application of each model.
- Top Cited PapersOpen Access
- 2 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , 2656395
Immune System and Hepatic Stellate Cells’ Crosstalk in Liver Fibrosis: Pathways and Therapeutic Potential
Liver fibrosis, characterized by the excessive deposition of extracellular matrix (ECM) driven by hepatic stellate cells (HSCs) activation, remains a critical challenge due to its progression to cirrhosis and hepatocellular carcinoma (HCC). This review clarifies the complex crosstalk between the immune system and HSCs, highlighting key cellular players including macrophages, natural killer (NK) cells, regulatory T cells (Tregs), and their cytokine‐mediated signaling pathways that regulate fibrogenesis and fibrosis resolution. We describe pivotal molecular mechanisms such as transforming growth factor (TGF)‐β, platelet‐derived growth factor (PDGF), Wnt/β‐catenin, and NF‐κB signaling in HSCs modulation, emphasizing their interplay with immune responses. Novel therapeutic strategies targeting this complex immune–HSCs interaction, ranging from immunomodulatory agents, macrophage polarization, and NK cell‐based therapies, to stem cell‐derived exosomes, offer promising opportunities for preventing and reversing fibrosis. We further discuss innovative combination therapies integrating immunotherapies with antifibrotic agents, personalized strategies based on immune profiling, and the challenges of immune heterogeneity in fibrosis management. This review discusses recent advances in molecular interplay of immune system and HSCs, highlighting novel therapeutic targets, and future perspectives for managing chronic liver diseases.
- 2 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , 2656395
Top Cited PapersOpen AccessImmune System and Hepatic Stellate Cells’ Crosstalk in Liver Fibrosis: Pathways and Therapeutic Potential
Liver fibrosis, characterized by the excessive deposition of extracellular matrix (ECM) driven by hepatic stellate cells (HSCs) activation, remains a critical challenge due to its progression to cirrhosis and hepatocellular carcinoma (HCC). This review clarifies the complex crosstalk between the immune system and HSCs, highlighting key cellular players including macrophages, natural killer (NK) cells, regulatory T cells (Tregs), and their cytokine‐mediated signaling pathways that regulate fibrogenesis and fibrosis resolution. We describe pivotal molecular mechanisms such as transforming growth factor (TGF)‐β, platelet‐derived growth factor (PDGF), Wnt/β‐catenin, and NF‐κB signaling in HSCs modulation, emphasizing their interplay with immune responses. Novel therapeutic strategies targeting this complex immune–HSCs interaction, ranging from immunomodulatory agents, macrophage polarization, and NK cell‐based therapies, to stem cell‐derived exosomes, offer promising opportunities for preventing and reversing fibrosis. We further discuss innovative combination therapies integrating immunotherapies with antifibrotic agents, personalized strategies based on immune profiling, and the challenges of immune heterogeneity in fibrosis management. This review discusses recent advances in molecular interplay of immune system and HSCs, highlighting novel therapeutic targets, and future perspectives for managing chronic liver diseases.
- Open Access
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1) , e9547868
Noninvasive Biomarkers for Early Detection of Primary Sclerosing Cholangitis in Ulcerative Colitis
Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease strongly associated with ulcerative colitis (UC). Although uncommon, PSC‐associated ulcerative colitis (PSCUC) represents a distinct subtype of inflammatory bowel diseases characterized by a higher risk of colorectal and hepatobiliary cancers. Early diagnosis remains a challenging issue because of the lack of specific biomarkers. Bioinformatic analysis of Gene Expression Omnibus (GEO) datasets identified potential, specific, and noninvasive biomarkers via differential gene expression and functional enrichment. After processing the data, S100A8 and S100A12 were identified as candidate biomarkers for detecting PSC in patients with UC. S100A8 encodes one component of calprotectin, the S100A8/S100A9 heterodimer widely used as a marker of intestinal inflammation. These two genes are primarily involved in inflammation, immune responses, and leukocyte recruitment, making them potentially useful biomarkers for early detection in PSC in UC patients. These biomarkers offer potential implications for disease stratification and therapeutic targeting. Further validation in prospective clinical studies is warranted to confirm their diagnostic and prognostic utilities.
- 1 January 2026
- Published by Wiley in BioMed Research International
- Vol. 2026 (1) , e9547868
Open AccessNoninvasive Biomarkers for Early Detection of Primary Sclerosing Cholangitis in Ulcerative Colitis
Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease strongly associated with ulcerative colitis (UC). Although uncommon, PSC‐associated ulcerative colitis (PSCUC) represents a distinct subtype of inflammatory bowel diseases characterized by a higher risk of colorectal and hepatobiliary cancers. Early diagnosis remains a challenging issue because of the lack of specific biomarkers. Bioinformatic analysis of Gene Expression Omnibus (GEO) datasets identified potential, specific, and noninvasive biomarkers via differential gene expression and functional enrichment. After processing the data, S100A8 and S100A12 were identified as candidate biomarkers for detecting PSC in patients with UC. S100A8 encodes one component of calprotectin, the S100A8/S100A9 heterodimer widely used as a marker of intestinal inflammation. These two genes are primarily involved in inflammation, immune responses, and leukocyte recruitment, making them potentially useful biomarkers for early detection in PSC in UC patients. These biomarkers offer potential implications for disease stratification and therapeutic targeting. Further validation in prospective clinical studies is warranted to confirm their diagnostic and prognostic utilities.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Genomics
- Vol. 2026 (1)
Extracellular Matrix–Associated Biomarkers for Hepatocellular Carcinoma: Insights From Machine Learning and Single‐Cell Analysis
The 5‐year overall survival rate for hepatocellular carcinoma (HCC) patients remains below 20%. Alterations in the extracellular matrix (ECM) are increasingly recognized as central drivers of HCC initiation and progression. This study applied a system biology framework integrating omics data and machine learning to analyze gene expression and regulatory networks in HCC using The Cancer Genome Atlas. Eight ECM‐associated genes ( CSPG4 , CD34 , C1orf35 , ESM1 , MAPT , PLXDC1 , STC2 , and THBS4 ) were identified as upregulated diagnostic biomarkers with strong discriminatory power. Among them, MAPT , PLXDC1 , and STC2 showed significant associations with poor overall survival, defining a prognostic subset. Validation in the GSE104310 and GSE144269 datasets confirmed consistent expression patterns across cohorts. Functional enrichment linked these genes to tissue remodeling and angiogenesis. Single‐cell RNA sequencing revealed MAPT upregulation in T cells, PLXDC1 enrichment in cancer‐associated fibroblasts, and mild STC2 elevation in tumor‐associated macrophages and endothelial cells. These findings identify key ECM‐based biomarkers with potential for early detection, prognosis, and therapeutic targeting in HCC.
- 1 January 2026
- Published by Wiley in International Journal of Genomics
- Vol. 2026 (1)
Open AccessExtracellular Matrix–Associated Biomarkers for Hepatocellular Carcinoma: Insights From Machine Learning and Single‐Cell Analysis
The 5‐year overall survival rate for hepatocellular carcinoma (HCC) patients remains below 20%. Alterations in the extracellular matrix (ECM) are increasingly recognized as central drivers of HCC initiation and progression. This study applied a system biology framework integrating omics data and machine learning to analyze gene expression and regulatory networks in HCC using The Cancer Genome Atlas. Eight ECM‐associated genes ( CSPG4 , CD34 , C1orf35 , ESM1 , MAPT , PLXDC1 , STC2 , and THBS4 ) were identified as upregulated diagnostic biomarkers with strong discriminatory power. Among them, MAPT , PLXDC1 , and STC2 showed significant associations with poor overall survival, defining a prognostic subset. Validation in the GSE104310 and GSE144269 datasets confirmed consistent expression patterns across cohorts. Functional enrichment linked these genes to tissue remodeling and angiogenesis. Single‐cell RNA sequencing revealed MAPT upregulation in T cells, PLXDC1 enrichment in cancer‐associated fibroblasts, and mild STC2 elevation in tumor‐associated macrophages and endothelial cells. These findings identify key ECM‐based biomarkers with potential for early detection, prognosis, and therapeutic targeting in HCC.
- Open Access
- 2 June 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (2) , 314-325
M2 macrophages-based immunotherapy: A new therapeutic approach in liver fibrosis
Liver fibrosis (LF) is a pathological condition resulting from a chronic inflammatory response to multiple etiological factors, including viral infections, excessive alcohol consumption, and metabolic disorders. The important role of macrophages in this process, especially the M2 subtype, has attracted attention as a potential target for macrophage-based immunotherapy. M2 macrophages have anti-inflammatory and reparative properties that enable them to modulate the immune response and facilitate repairing damaged tissues. They participate in reducing fibrogenic features in term of gene expression and histological markers associated with LF. These cells phagocytose apoptotic cells and matrix components. M2 macrophage-based immunotherapy has shown great potential in ameliorating LF through mechanisms involving the IL-10/STAT3 and TGF-β/SMAD signaling pathways, which are essential in suppressing the pro-inflammatory response and supporting tissue regeneration. However, significant challenges such as individual resistance to therapy and the potential for promoting fibrosis suggest that further development and research are needed to optimize the safety and efficacy of this therapy in clinical applications. This study provides comprehensive insights into the role of M2 macrophages in LF and explores their potential as an innovative therapeutic approach in treating LF.
- 2 June 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (2) , 314-325
Open AccessM2 macrophages-based immunotherapy: A new therapeutic approach in liver fibrosis
Liver fibrosis (LF) is a pathological condition resulting from a chronic inflammatory response to multiple etiological factors, including viral infections, excessive alcohol consumption, and metabolic disorders. The important role of macrophages in this process, especially the M2 subtype, has attracted attention as a potential target for macrophage-based immunotherapy. M2 macrophages have anti-inflammatory and reparative properties that enable them to modulate the immune response and facilitate repairing damaged tissues. They participate in reducing fibrogenic features in term of gene expression and histological markers associated with LF. These cells phagocytose apoptotic cells and matrix components. M2 macrophage-based immunotherapy has shown great potential in ameliorating LF through mechanisms involving the IL-10/STAT3 and TGF-β/SMAD signaling pathways, which are essential in suppressing the pro-inflammatory response and supporting tissue regeneration. However, significant challenges such as individual resistance to therapy and the potential for promoting fibrosis suggest that further development and research are needed to optimize the safety and efficacy of this therapy in clinical applications. This study provides comprehensive insights into the role of M2 macrophages in LF and explores their potential as an innovative therapeutic approach in treating LF.
- 14 January 2025
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 261, 108607
Targeting CD84 protein on myeloid-derived suppressor cells as a novel immunotherapy in solid tumors
- 14 January 2025
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 261, 108607
Targeting CD84 protein on myeloid-derived suppressor cells as a novel immunotherapy in solid tumors
- Open Access
- 1 January 2025
- Published by Wiley in BioMed Research International
- Vol. 2025 (1) , 5551687
Overexpression of KDM6A in Hepatoma Cells Induces Hepatocytic Differentiation and Attenuates Proliferation Rate, Colony Formation, and Migration Capacities
Objective: Despite the remarkable advances in approved therapeutic approaches, the recurrence rate of hepatocellular carcinoma (HCC) is very high after treatment. Therefore, introducing innovative therapeutic modalities such as targeted molecular therapies is inevitable. Lysine demethylase 6A ( KDM6A ) is a member of the KDM6 family with histone demethylase activity. This gene frequently mutates in different cancers, and its mutations are associated with the increased likelihood of carcinogenesis. This study is aimed at evaluating if inducing KDM6A expression could attenuate cancerous features of HCC cells. Method: A lentiviral‐based vector was used to induce KDM6A expression in Huh‐7 cells. The impact of KDM6A overexpression on the cancerous phenotype of HCC cells was assessed by measuring proliferation rate, migration and colony formation capacity, and differentiation induction toward hepatocytes. Results: KDM6A overexpression significantly altered cellular morphology, proliferation rate, cell cycle pattern, colony formation, and migration capacity of HCC cells. In addition, induction of differentiation toward hepatocytic fate resulted in down/upregulation of epithelial–mesenchymal transition (EMT) markers associated with the cadherin switch. Furthermore, the expressions of ALB and HNF4α , key hepatocytic hallmarks, were increased. Conclusion: Overexpression of KDM6A could be used as a potential noninvasive molecular therapeutic strategy to prevent metastasis and recurrence rate in HCC.
- 1 January 2025
- Published by Wiley in BioMed Research International
- Vol. 2025 (1) , 5551687
Open AccessOverexpression of KDM6A in Hepatoma Cells Induces Hepatocytic Differentiation and Attenuates Proliferation Rate, Colony Formation, and Migration Capacities
Objective: Despite the remarkable advances in approved therapeutic approaches, the recurrence rate of hepatocellular carcinoma (HCC) is very high after treatment. Therefore, introducing innovative therapeutic modalities such as targeted molecular therapies is inevitable. Lysine demethylase 6A ( KDM6A ) is a member of the KDM6 family with histone demethylase activity. This gene frequently mutates in different cancers, and its mutations are associated with the increased likelihood of carcinogenesis. This study is aimed at evaluating if inducing KDM6A expression could attenuate cancerous features of HCC cells. Method: A lentiviral‐based vector was used to induce KDM6A expression in Huh‐7 cells. The impact of KDM6A overexpression on the cancerous phenotype of HCC cells was assessed by measuring proliferation rate, migration and colony formation capacity, and differentiation induction toward hepatocytes. Results: KDM6A overexpression significantly altered cellular morphology, proliferation rate, cell cycle pattern, colony formation, and migration capacity of HCC cells. In addition, induction of differentiation toward hepatocytic fate resulted in down/upregulation of epithelial–mesenchymal transition (EMT) markers associated with the cadherin switch. Furthermore, the expressions of ALB and HNF4α , key hepatocytic hallmarks, were increased. Conclusion: Overexpression of KDM6A could be used as a potential noninvasive molecular therapeutic strategy to prevent metastasis and recurrence rate in HCC.
- 6 July 2024
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 759, 110086
Leech, potato, and tomato carboxypeptidase inhibitors against Anopheles stephensi carboxypeptidase B1 and B2
- 6 July 2024
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 759, 110086
Leech, potato, and tomato carboxypeptidase inhibitors against Anopheles stephensi carboxypeptidase B1 and B2